Key result
Emerging Lp(a)-lowering therapies show substantial promise for reducing residual atherosclerotic risk.
Answers are grounded in this paper and cite their sources.
This review highlights the emerging role of novel non-statin agents, such as RNA-targeted therapies and CETP inhibitors, in addressing residual atherosclerotic risk by lowering Lp(a) and LDL-C.
Cardiovascular disease remains the leading global cause of mortality. Residual atherosclerotic risk persists despite intensive low-density lipoprotein cholesterol (LDL-C) lowering, in part due to genetically determined lipoprotein(a) [(Lp(a)}. Strong associations exist between increased atherogenic lipoproteins and cardiovascular risk. Although Lp(a) is an independent risk factor, most international guidelines have not yet endorsed therapeutic lowering of plasma Lp(a), while novel, non-statin agents now show promising reductions in Lp(a). Lifestyle and traditional therapies exert minimal effects on Lp(a); however, ribonucleic acid (RNA)-targeted agents and selective cholesteryl ester transfer protein (CETP) inhibition show substantial promise. Multiple RNA-based therapeutics are in development – most advanced is the antisense oligonucleotide pelacarsen (Phase 3, Lp(a)HORIZON). Obicetrapib, a highly selective CETP inhibitor, further lowers LDL-C and apoB when added to maximally tolerated therapy. This chapter reviews Lp(a) biology, epidemiology, clinical measurement, and the evidence base for emerging Lp(a)-lowering therapies (pelacarsen, olpasiran, lepodisiran, zerlasiran, and muvalaplin) as well as obicetrapib and advanced triglyceride-lowering agents. Practical pathways for screening and implementation in preventive cardiology are provided.
No takes yet. Share an insight, caveat, or question.
Palimkar et al. (2025) conducted a review in Cardiovascular disease. Lp(a)-lowering therapies and CETP inhibitors (e.g., pelacarsen, obicetrapib) was evaluated. Emerging therapies including pelacarsen and obicetrapib show substantial promise for lowering Lp(a) and reducing residual atherosclerotic risk in cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: